Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Construction in Progress (2021 - 2023)

SAB Biotherapeutics' Construction in Progress history spans 3 years, with the latest figure at $329617.0 for Q1 2023.

  • For Q1 2023, Construction in Progress changed N/A year-over-year to $329617.0; the TTM value through Mar 2023 reached $329617.0, changed N/A, while the annual FY2022 figure was $137811.0, 35.47% down from the prior year.
  • Construction in Progress reached $329617.0 in Q1 2023 per SABSW's latest filing, up from $137811.0 in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $329617.0 in Q1 2023 to a low of $137811.0 in Q4 2022.
  • Average Construction in Progress over 3 years is $226997.3, with a median of $213564.0 recorded in 2021.
  • The largest YoY upside for Construction in Progress was 35.47% in 2022 against a maximum downside of 35.47% in 2022.
  • A 3-year view of Construction in Progress shows it stood at $213564.0 in 2021, then plummeted by 35.47% to $137811.0 in 2022, then skyrocketed by 139.18% to $329617.0 in 2023.
  • Per Business Quant, the three most recent readings for SABSW's Construction in Progress are $329617.0 (Q1 2023), $137811.0 (Q4 2022), and $213564.0 (Q4 2021).